Product
Supplier
Encyclopedia
Inquiry
Home > Food Additives > Nutrition Supplements > Fmoc-Ile-Aib-Leu-Asp(OtBu)-OH dideu Tirzepatide intermediates
Fmoc-Ile-Aib-Leu-Asp(OtBu)-OH dideu Tirzepatide intermediates buy - large image1
Fmoc-Ile-Aib-Leu-Asp(OtBu)-OH dideu Tirzepatide intermediates buy - image1

Fmoc-Ile-Aib-Leu-Asp(OtBu)-OH dideu Tirzepatide intermediates

Unit Price: Get Latest Price
Grade:

Pharmaceutical Grade

Content:

99%

Brand:

Dideu

Packaging:

25KG/DRUM

Price valid (until):

2023-12-20

Company Type:
Manufactory
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
7 days
Qualification:
Main Products:

Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

  • Product Description

  • Seller Information

  • Description
    COA, HPLC, Pls Contact 1010@dideu.com



      • Molecular Weight: 722.39

        Molecular Formula:C39H54N4O9

        Appearance: White to off-white powder

        Application: medical intermediate

        Delivery Time:  Available goods in stock

        Package: inside:double PE bags   outside:paper drum

        Port: any port in China

        Production Capacity: more than 10kg

        Purity: ≥98%

        Storage: store at under-20°C

        Transportation: CIF by air or DAP by courier, FOB, EX W Etc...





    Basic Info
    Product Name:

    Fmoc-Ile-Aib-Leu-Asp(OtBu)-OH Tirzepatide intermediates

    Categories:

    Nutrition Supplements

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Chemical Pesticides,Food Additives,Agrochemicals,Active Pharm Ingredients,Flavors and Fragrances,Chemical Catalyst

    Location:

    https://www.dideu.com/en/

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    7 days

    Total Annual Revenue:

    Above $100 million

    Total Employees:

    Above 1000

    Year of Establishment:

    2016

    Company Certificates
    • Shaanxi Dideu Medichem Co. LtdISO Certificate ISO Certificate
    • Shaanxi Dideu Medichem Co. LtdREACH REACH
    Company Profile
    ">Company Profile
  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.